Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold.

Tempus AI (TEM) shares gained 17.9% over the past month, outperforming peers like Claritev and iRhythm, driven by strong demand for healthcare AI. The company reported 28% revenue growth in its Data and Applications segment to $93.2M in Q2, with Insights revenues up 36%. However, TEM trades at a premium valuation of 6.59X sales versus the industry average of 4.70X, and its growth depends heavily on regulatory approvals and reimbursement decisions. Analysts recommend current holders maintain positions while prospective investors wait for a more favorable entry point.

The global AI in clinical trials market is projected to expand from USD 2.09 billion in 2026 to USD 18.62 billion by 2040, growing at a 17.0% CAGR. AI applications including patient recruitment, predictive analytics, digital twins, and automation are addressing key challenges in drug development timelines and trial efficiency. Oncology represents the largest therapeutic area, while Asia-Pacific shows significant growth potential. Key players include IQVIA, Medidata, Dassault Systemes, and emerging AI companies like Deep 6 AI and AiCure.

Despite 2026 being marked by macroeconomic headwinds, geopolitical pressures, and AI safety concerns, the S&P 500 remains just 2% off all-time highs. The article argues that price action speaks louder than negative headlines, and with retail investor sentiment at multi-year lows while stocks near record levels, historical patterns suggest a strong rally into year-end. Several stocks broke out on Thursday including AMD, Tempus AI, Moderna, Super Micro Computer, and Aya Gold & Silver.

Inspire Medical Systems (INSP) reported Q2 2026 earnings that beat estimates with adjusted EPS of 14 cents versus expected loss of 22 cents, and raised full-year 2026 guidance. However, U.S. revenues declined 9.6% year-over-year due to coding and reimbursement challenges, partially offset by strong 33.6% international revenue growth. The stock has declined 4.1% since earnings despite the Zacks Rank #1 (Strong Buy) rating.

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.

Nadja West, a director at Tempus AI, sold 3,000 shares for $161,700 on August 14 under a pre-established Rule 10b5-1 trading plan set up in May. Four days later, the stock rallied 24% following news that Moderna and Merck's cancer vaccine succeeded in late-stage trials. West retained 34,981 shares worth ~$1.8 million. The sale timing appears coincidental as it was scheduled months in advance, and the company reported strong Q2 results with 22% revenue growth and its first GAAP profit.

Tempus AI's Chief Legal Officer Andrew Polovin sold 30,075 shares worth $1.5 million in a non-discretionary transaction to cover tax withholding obligations from RSU vesting. The sale occurred during a 75% stock rally driven by positive results from a Moderna-Merck cancer vaccine trial validating Tempus's genomic sequencing technology. The company reported 22% revenue growth to $382.5 million last quarter and achieved its first GAAP profit, though it remains unprofitable on a TTM basis with -$254.4 million net income.

Ryan Fukushima, CEO of Tempus AI's data business, sold 41,095 shares (~$2.0 million) on August 18 through a non-discretionary sell-to-cover transaction to satisfy tax withholding obligations from RSU vesting. Despite the sale, Fukushima maintains a substantial stake of approximately 624,000 total shares. His data segment showed strong growth with 28% year-over-year revenue increase to $93.2 million, outpacing the diagnostics division.

Law firm Wohl & Fruchter is investigating whether the Personalis board acted in shareholders' best interests regarding the proposed $16.25 per share sale to Tempus AI. Since the announcement on July 20, 2026, Personalis shares have fallen approximately 14% due to the deal's partial stock consideration and Tempus share price decline. Shareholders have expressed disappointment with the transaction.

Law firm Julie & Holleman is investigating Personalis' proposed acquisition by Tempus AI for $16.25 per share, raising concerns about fair value and potential conflicts of interest given Tempus' existing significant equity stake and strategic partnership with Personalis since 2023.